Study guide

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR)

NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacist Licensure & Reciprocity

1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement

2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios

2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles

3 Chapter 3: Prescriptive Authority & Practitioner Categories

3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members

4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR

5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements

5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing

6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling

6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)

7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose

7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)

8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping

8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)

9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety

9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs

10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution

10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution

11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>

11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy

12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR)

Key Takeaways Explain This Topic AI

The Omnibus Budget Reconciliation Act of 1990 (OBRA '90) established federal standards for Medicaid patients, which state pharmacy boards subsequently extended to all pharmacy patients.

Prospective Drug Utilization Review (ProDUR) is a mandatory point-of-sale screening conducted by the pharmacist prior to dispensing every prescription.

OBRA '90 mandates seven specific DUR screening elements: therapeutic duplication, drug-disease contraindications, drug-drug interactions, incorrect drug dosage or duration, drug-allergy interactions, clinical abuse/misuse, and over/under-utilization.

Alert fatigue does not relieve pharmacists of legal liability; pharmacists must independently evaluate and document resolutions for all high-risk prospective DUR warnings before dispensing.

Prospective DUR focuses on real-time individual patient safety at the time of dispensing, whereas Retrospective DUR analyzes aggregate historical claims data.

Last updated: July 2026

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR)

The Omnibus Budget Reconciliation Act of 1990 (OBRA '90) represents one of the most transformative federal statutes in the history of American pharmacy practice. Enacted by the United States Congress, OBRA '90 fundamentally shifted the legal standard of care for pharmacists from a traditional focus on accurate dispensing (product-oriented practice) to comprehensive pharmaceutical care and patient safety (patient-oriented practice).

Although OBRA '90 was passed as a federal law specifically tying pharmacy practice mandates to state Medicaid program funding eligibility, individual State Boards of Pharmacy across all 50 states subsequently incorporated these exact standards into their pharmacy practice acts and administrative rules. Consequently, as tested on the Multistate Pharmacy Jurisprudence Examination (MPJE), the mandates of OBRA '90 apply to all retail and community pharmacy patients , regardless of whether their prescriptions are paid for by Medicaid, commercial insurance, or cash.

The Three Pillars of OBRA '90

OBRA '90 established a tripartite framework designed to ensure that medication therapy is medically necessary, appropriate, and unlikely to result in adverse medical outcomes. The three core operational pillars established under OBRA '90 are:

Prospective Drug Utilization Review (ProDUR): Real-time evaluation of prescription drug therapy by the dispensing pharmacist at the point of sale prior to dispensing.

Mandatory Patient Counseling Offer: The affirmative obligation of the pharmacy to offer face-to-face verbal counseling to patients or their caregivers regarding dispensed medications.

Patient Profile Maintenance & Retrospective DUR: The obligation to collect and maintain comprehensive patient drug histories and participate in retrospective claims data analysis overseen by state DUR boards.

Mechanics of Prospective Drug Utilization Review (ProDUR)

Prospective Drug Utilization Review (ProDUR) is an interactive, point-of-sale screening process performed by the licensed pharmacist prior to dispensing a new or refill prescription. The primary objective of ProDUR is to identify, evaluate, and resolve potential drug therapy problems before the patient physically receives the medication.

Modern pharmacy dispensing software automatically checks electronic prescription data against the patient's centralized profile and generates clinical warnings. However, the legal responsibility for performing ProDUR rests entirely on the licensed pharmacist , not the software vendor or computer system.

The 7 Mandatory DUR Screening Categories

Under federal OBRA '90 regulations (42 CFR § 456.705) and corresponding state pharmacy regulations, the pharmacist must screen every prescription presented for dispensing against seven mandatory clinical categories :

1. Therapeutic Duplication

Therapeutic duplication occurs when a patient is prescribed two or more medications containing the same active ingredient or belonging to the same pharmacological/therapeutic class without clinical justification.

Clinical Example: A patient presenting a new prescription for lisinopril while currently taking enalapril, or concurrently taking two systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen, which increases gastrointestinal toxicity without additive efficacy.

2. Drug-Disease Contraindications

Drug-disease contraindications occur when a prescribed drug has the potential to exacerbate an existing medical condition or chronic disease state.

Clinical Example: Prescribing a non-selective beta-blocker (e.g., propranolol) to a patient with documented severe asthma or Chronic Obstructive Pulmonary Disease (COPD), triggering bronchospasm, or dispensing systemic oral decongestants (e.g., pseudoephedrine) to a patient with uncontrolled severe hypertension.

3. Drug-Drug Interactions

Drug-drug interactions occur when co-administered medications alter the efficacy, absorption, metabolism, or toxicity profile of one or both drugs. The screening must also evaluate potential interactions between prescription drugs and non-prescription (OTC) medications or dietary supplements listed in the patient profile.

Clinical Example: Dispensing fluconazole or amiodarone to a patient stabilized on warfarin, leading to severe cytochrome P450 inhibition, elevated International Normalized Ratio (INR), and life-threatening hemorrhage risk.

4. Incorrect Drug Dosage or Duration of Treatment

Pharmacists must evaluate whether the prescribed dose, frequency, route, and total duration of therapy fall within established FDA-approved or evidence-based clinical guidelines, taking into account patient-specific factors such as renal function, hepatic function, age, and weight.

Clinical Example: Dispensing oral ketorolac for a 14-day supply (federal guidelines explicitly limit ketorolac therapy to a maximum of 5 consecutive days due to severe renal impairment and GI ulceration risks), or failing to adjust renal dosing for gabapentin or levofloxacin in an elderly patient with reduced CrCl.

5. Drug-Allergy Interactions and Cross-Reactivity

Pharmacists must verify that the prescribed drug does not conflict with documented drug allergies or known hypersensitivity reactions recorded in the patient profile, including evaluating potential immunological cross-reactivity.

Clinical Example: Dispensing amoxicillin to a patient with a documented history of penicillin-induced anaphylaxis, or dispensing a sulfonamide antibiotic (e.g., sulfamethoxazole/trimethoprim) to a patient with a known severe sulfa allergy.

6. Clinical Abuse or Misuse

The pharmacist must screen for patterns indicative of irrational drug use, psychological dependency, addiction, diversion, or patient misdirection. This includes monitoring refill frequencies, overlapping prescriptions from multiple prescribers ("doctor shopping"), and early refill requests for controlled substances.

Clinical Example: A patient requesting a 30-day refill for oxycodone/acetaminophen 12 days after the previous fill was dispensed, or obtaining concurrent benzodiazepine and opioid prescriptions from three different prescribers.

7. Drug-Prescriber / Over- and Under-Utilization

Pharmacists must assess whether the patient is overutilizing (taking higher doses or refilling too frequently) or underutilizing (non-adherence, delayed refills) their prescribed regimen. Under-utilization of maintenance therapies for chronic conditions (e.g., statins, antihypertensives, inhalers) represents a major cause of preventable hospitalizations.

Pharmacist Legal Duty & Overriding Alert Fatigue

In modern practice, pharmacy computer systems frequently generate automated alert pop-ups for minor or theoretical drug interactions. This phenomenon, known as alert fatigue , creates a significant risk that pharmacists might bypass pop-ups without conducting a meaningful clinical review.

On the MPJE, it is a critical legal rule that computerized DUR alerts do not satisfy or shift the pharmacist's legal liability . If a computer system flags a high-risk DUR warning (such as a severe drug interaction or contraindication) and the pharmacist overrides the alert without conducting a proper evaluation, contacting the prescriber, or documenting a clinical rationale, the pharmacist is held legally liable for any resulting patient injury under both tort law and administrative pharmacy board discipline.

When a prospective DUR screening flags a potential problem, the pharmacist must exercise professional judgment to determine the appropriate intervention:

Gather Patient Context: Review patient profile notes, previous refill history, or consult the patient directly.

Contact the Prescriber: If a clinically significant contraindication, incorrect dose, or major interaction exists, the pharmacist must contact the prescriber to discuss alternative therapy or monitoring.

Refuse to Dispense: If the prescriber insists on an unsafe regimen that threatens patient safety, the pharmacist has the legal authority and duty to refuse to dispense the prescription.

Document Resolution: All DUR interventions, prescriber consultations, and clinical justifications must be contemporaneously documented in the pharmacy record system.

Prospective DUR vs. Retrospective DUR Comparison

Feature Prospective DUR (ProDUR) Retrospective DUR (RetroDUR)

Timing of Review Before the medication is dispensed (Point-of-Sale) After the medication has been dispensed (Post-Facto)

Primary Responsible Party Dispensing Licensed Pharmacist State Medicaid Agency, HMO, PBM, DUR Board

Primary Target Scope Individual patient and single prescription transaction Aggregate population data across thousands of claims

Key Focus Areas Real-time safety: allergies, interactions, dosing, duplication Pattern detection: fraud, abuse, prescribing trends, cost

Action Outcome Immediate intervention, dosage edit, or refusal to dispense Educational detailing, prescriber audits, policy changes

Summary Table: 7 Mandatory DUR Screening Categories

Category Primary Focus Representative MPJE Scenario

Therapeutic Duplication Same class/mechanism prescribed concurrently Concurrent filling of two oral NSAIDs or two ACE inhibitors

Drug-Disease Contraindication Exacerbation of existing disease state Beta-blockers in asthma; pseudoephedrine in severe hypertension

Drug-Drug Interaction Altered drug effects or increased toxicity Warfarin + Fluconazole; Nitroglycerin + Sildenafil

Incorrect Dosage/Duration Out-of-bounds dosing or excessive duration Ketorolac therapy exceeding 5 days total duration

Drug-Allergy Interaction Hypersensitivity and cross-reactivity Amoxicillin dispensed to patient with penicillin anaphylaxis history

Clinical Abuse/Misuse Overutilization, early refills, diversion Controlled substance refill requested 15 days early

Over/Under-Utilization Non-adherence or excessive dosing patterns Missing 4 months of maintenance antihypertensive refills

Loading diagram... Prospective Drug Utilization Review (ProDUR) Workflow